Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Creative Bio of Guangzhou Raises $45 Million for Early Colorectal Cancer Test

publication date: Apr 12, 2019

Creative Biosciences, a Guangzhou cancer screening and cancer diagnostic kit maker, raised $45 million from IDG Capital and CDH Investment in a Series B round. Creative will use the funds to market Colosafe, its early diagnostic kits for colon cancer. The test, which was approved by China's NMPA in late 2018, is based on fecal genetic testing. Creative says Colosafe is priced at less than half the US cost for similar tests, but has a higher detection specificity than its competitors. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020